key: cord-0756409-8856pfzw authors: Chavda, Vivek P.; Gajjar, Normi; Shah, Nirav; Dave, Divyang J. title: Darunavir Ethanolate: Repurposing an Anti-HIV Drug in COVID-19 Treatment date: 2021-10-22 journal: European Journal of Medicinal Chemistry Reports DOI: 10.1016/j.ejmcr.2021.100013 sha: f1d47137a017cf43faf59f6d5d33cd559aa590b1 doc_id: 756409 cord_uid: 8856pfzw Antivirals already on the market and expertise gained from the SARS and MERS outbreaks are gaining momentum as the most effective way to combat the coronavirus outbreak. SARS-CoV-2 has caused considerable mortality due to respiratory failure, highlighting the immediate need for successful therapies as well as the long-term need for antivirals to combat potential emergent coronaviruses. There are constant viral mutations are being observed due to which world is experiencing different waves of SARS-CoV-2. If our understanding of the virology and clinical presentation of COVID-19 grows, so does the pool of possible pharmacological targets. In COVID-19, the difficulties of proper analysis of current pre-clinical/clinical data as well as the creation of new evidence concerning drug repurposing will be crucial. The current manuscript aims to evaluate the repurposing of an anti-HIV drug Darunavir Ethanolate in COVID-19 treatment with in silico study and we discuss the therapeutic progress of Darunavir Etanolate, to prevent SARS-CoV-2 replication, which supports its clinical assessment for COVID-19 therapy. Trimeric S glycoprotein is a fusion protein of class I and encourages its adherence to the host 80 receptor [8, 9] . These proteins' operation aids in the transport of the viral genome to the 81 replica-transcriptase (RTC) complex, which then inserts the encapsidated genome into viral 82 particles. A fifth structural protein, hemagglutinin-esterase (HE), is present in a subset of beta 83 coronaviruses and aids S-protein-mediated cell entry and viral propagation via the mucosa 84 [10]. 85 As a receptor alphacoronaviruses use APN[11] , Angiostensin converter (ACE2) enzymes are 86 used as receptors by SARS-CoV, SARS-CoV-2, and HCoV-NL63 [12] [13] [14] [15] . S1 and S2 are the 87 S protein's two regions. The interaction between S1 and its cognate receptor causes the S 88 protein to change/modify [16] . The virus must gain access to the host cell cytosol following After the viral presentation by APC, the innate immune system of the host instantly gets 134 activated to eliminate the viral particles from the body without injuring the host cells. The 135 innate immune system is responsible for protecting the host cells until the acquired immunity 136 gets developed maybe within 7 or more days after the infection [32]. APC system will further 137 activate the B cells and cytotoxic T cells. Drug repurposing is also known as drug reprofiling, repositioning, or re-tasking. It is the 185 approach to identify the newer uses of previously approved or investigational drugs other Table 2 ) have been tested for repurposing to treat COVID-19. As of now, remdesivir and favipiravir are used to manage the disease condition but they have safety is also the concern. As per the clinical data obtained, the above two antiviral agents are 202 not much effective in managing COVID-19. authorship for the work. Figure 1 and 3 CoV-2 infection is effectively treated and prevented by EIDD-2801. Nature World Health Organization (WHO) Primary exposure to SARS-CoV-2 440 protects against reinfection in rhesus macaques Clinical and immunological 443 features of severe and moderate coronavirus disease 2019 Immune responses and pathogenesis of SARS-446 CoV-2 during an outbreak in Iran: Comparison with SARS and MERS SARS-CoV-2-reactive T cells in patients and healthy donors Cells Provide Substantial Protection from Lethal Severe Acute 452 Respiratory Syndrome Coronavirus Infection Food additives Immune responses in COVID-19 and potential 456 vaccines: Lessons learned from SARS and MERS epidemic The 459 pathophysiology of SARS-CoV-2: A suggested model and therapeutic approach Pathogenic human coronavirus infections: causes and 462 consequences of cytokine storm and immunopathology Chloroquine in fighting COVID-19: 495 good, bad, or both? Efficacy of hydroxychloroquine 498 in patients with COVID-19: Results of a randomized clinical trial Hydroxychloroquine on Clinical Status at 14 Days in Hospitalized Patients with 502 COVID-19: A Randomized Clinical Trial A five-505 day course of ivermectin for the treatment of COVID-19 may reduce the duration of 506 illness Use of ivermectin in the treatment of Covid-19: A pilot trial Effect of Ivermectin on Time to Resolution of Symptoms among Adults with Mild 512 COVID-19: A Randomized Clinical Trial Ivermectin as a 515 potential treatment for mild to moderate COVID-19 -A double blind randomized 516 placebo-controlled trial Beneficial effects of colchicine for moderate to severe COVID-19: An interim analysis 519 of a randomized, double-blinded Efficacy of Colchicine in Non-Hospitalized 522 Patients with COVID-19 Antiviral activity and safety of Reduce Severity of Coronavirus Disease 2019 Sepsis: A First 541 Observation Camostat mesylate inhibits SARS-CoV-2 activation by TMPRSS2-related proteases 545 and its metabolite GBPA exerts antiviral activity Umifenovir) on COVID-19: a randomized controlled trial Efficacy of umifenovir in the treatment 551 of mild and moderate COVID-19 patients Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients with Moderate COVID-19: A Randomized Clinical Trial Methylprednisolone or dexamethasone, which one is superior corticosteroid in 561 the treatment of hospitalized COVID-19 patients: a triple-blinded randomized 562 controlled trial Successful use of methylprednisolone for 565 treating severe COVID-19 Lopinavir pharmacokinetics in COVID-19 patients Lopinavir-571 ritonavir in patients admitted to hospital with COVID-19 (RECOVERY): a 572 randomised, controlled, open-label, platform trial A Trial of Lopinavir-Ritonavir 575 in Adults Hospitalized with Severe Covid-19 lopinavir/ritonavir in the treatment of SARS: Initial virological and clinical findings Sarilumab in 581 patients admitted to hospital with severe or critical COVID-19: a randomised, double-582 blind, placebo-controlled, phase 3 trial Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with 586 systemic hyperinflammation: An open-label cohort study Beneficial 589 impact of Baricitinib in COVID-19 moderate pneumonia; multicentre study Baricitinib for COVID-19: a 592 suitable treatment? kinase 1/2 inhibitor ruxolitinib in COVID-19 with severe systemic hyperinflammation Ruxolitinib in treatment of 598 severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized 599 controlled trial Patients Hospitalized with Covid-19 Pneumonia Tocilizumab in COVID-19 : some clarity amid controversy Efficacy of Tocilizumab in Patients Hospitalized with Covid-19 Efficacy and tolerability of 610 bevacizumab in patients with severe Covid-19 Extraordinary Survival Benefits of Severe and Critical Patients with COVID-19 by Immune Modulators: The Outcome of a Clinical Trial in Bangladesh Clinical 618 Characteristics and Outcomes of Coronavirus Disease Randomized Clinical Trial of the Efficacy and Safety of Interferon -1a in Treatment of 623 Severe COVID-19 Interferon β-1b in treatment of severe COVID-19: A randomized clinical trial Unrevealing sequence and structural 629 features of novel coronavirus using in silico approaches: The main protease as 630 molecular target A joint research team of Shanghai Institute of Materia Medica, Chinese 632 Academy of Sciences and Shanghai University of Science and Technology has 633 discovered a batch of old and traditional Chinese medicines that may have therapeutic 634 effects on new pneumonia Severe acute respiratory syndrome 638 coronavirus-2 (SARS-CoV-2): a global pandemic and treatment strategies Volatile molecules for COVID-19: A possible pharmacological strategy? 642 AutoDock Vina: improving the speed and accuracy of docking with a function, efficient optimization and multithreading Darunavir/Cobicistat vs. Lopinavir/Ritonavir in COVID-647 19 Pneumonia in Qatar (DOLCI) Lack of evidence to support use of darunavir-based treatments for SARS-650 Darunavir and Cardiovascular Risk: Evaluating the Data to 653 Inform Clinical Care Repurposing an Anti HIV Drug in COVID-19 treatment  Studies for repurposing of drugs for COVID-19 have been included